NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced results from three key abstracts presented at the 24th World IFSO Congress. The abstracts examine the Elipse Program—featuring the Elipse Balloon, the world’s first and only procedureless medical device for weight loss—and show significant decreases in both weight and cardiovascular disease markers, such as LDL cholesterol and hemoglobin A1c, in patients who have used the balloon for weight loss. The Elipse Balloon received its European Union CE mark in 2015 and is currently available at more than 100 weight loss centers in countries across Europe, the Middle East, and South America.
“We’re pleased that these three studies highlight the safety, effectiveness, and versatility of the Elipse Program,” says Dr. Roberta Ienca of Clinica Nuova Villa Claudia in Rome, Italy and lead author of all three studies. “As obesity rates continue to rise around the world, a balloon that does not require surgery, endoscopy, or anesthesia has the potential to be a first-line weight loss option and help decrease concomitant conditions, such as high cholesterol, which can often accompany obesity and lead to cardiovascular disease.”
The abstracts were presented on September 5th and 7th and include:
- Elipse Procedureless Gastric Balloon for Weight Loss: Multi-Center Experience in 1,623 Patients: Selected as one of IFSO’s Top 10 abstracts, this is one of the largest gastric balloon data sets ever collected. The research was conducted across 19 weight loss centers in seven countries in patients with a minimum body mass index (BMI) of 27kg/m2 enrolled in the Elipse Program, which includes the Elipse Balloon and the Allurion Bluetooth® scale and smartphone application. Results demonstrate an average weight loss of 12.8kg (28lbs) and BMI reduction of 4.9kg/m2. Statistically significant reductions in LDL cholesterol, triglycerides, and hemoglobin A1c (HbA1c) were also reported.
- Does Sequential Elipse Balloon Treatment Augment Weight Loss: Safety and Efficacy in 30 Overweight and Obese Patients: This study examined patients who repeated the Elipse Program. After the first balloon, average weight loss was 13.4kg (29.5lbs) and BMI loss was 5kg/m2. Patients who remained indicated for balloon therapy were offered a second balloon. Repeat balloon use resulted in an additional average weight loss of 7.3kg (16lbs) and additional BMI loss of 2.6kg/m2. Results indicate an aggregate weight loss of more than 20kg may be possible with repeat balloon use.
- Multicenter Experience with the Elipse Procedureless Gastric Balloon in Obese Adolescents: Researchers studied 50 adolescents from six weight loss centers across four countries who enrolled in the Elipse Program. Results demonstrate an average weight loss of 13.2kg (29lbs) and BMI reduction of 4.8kg/m2. No serious adverse events were reported.
Unlike other weight loss balloons on the market, the Elipse Balloon is designed to be placed and removed without surgery, endoscopy, or anesthesia. It is swallowed in a capsule during an outpatient office visit and is designed to remain in the stomach for approximately four months, after which it opens and passes naturally from the body. More than 15,000 devices have already been distributed.
“These presentations underscore the impact the Elipse Program can have on overweight and obese individuals treated by a variety of practitioners in different clinical settings all over the world,” says Dr. Ram Chuttani, Allurion’s Chief Medical Officer. “In addition, we believe the studies highlight the utility of Allurion’s Bluetooth smart scale and smartphone application when used in concert with a supervised nutrition program to create a 360-degree weight loss experience.”
About the Elipse Program
At the heart of the Elipse Program is the Elipse Balloon—a procedureless weight loss device that is designed to be swallowed and removed without surgery, endoscopy, or anesthesia. The Elipse Balloon received its European Union CE mark in 2015 and is currently available in Europe, the Middle East, and South America. It is not approved by the FDA and is not currently available commercially in the United States. The Elipse Balloon is not approved for use in adolescents.
The Elipse Balloon is made of a thin, flexible polymer film. The device is swallowed in a capsule and filled with liquid through a thin delivery catheter, which is then detached. The balloon is designed to remain in the stomach for approximately four months, after which it opens, allowing it to empty and pass naturally from the body without the need for a removal procedure.
The Elipse Program also features Allurion’s Bluetooth smart scale and smartphone application that, in concert with a supervised nutrition program, create a 360-degree weight loss experience.
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable, and trusted experiences. The company's flagship product, the Elipse Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion, or on Twitter @alluriontech.
